Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.
Ferreira M, Bejan-Angoulvant T, Marchand-Adam S, Mousset E, Mureau E, Jouneau S, Nunes H, Montani D, Chenivesse C, Cadranel J, Bonniaud P, Crestani B, Cottin V, Caille A; OrphaLung.. Ferreira M, et al. Among authors: cottin v. Respir Med Res. 2024 Nov 28;87:101144. doi: 10.1016/j.resmer.2024.101144. Online ahead of print. Respir Med Res. 2024. PMID: 39693827
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.
Jenkins RG, Cottin V, Nishioka Y, Noth I, White ES, Ittrich C, Diefenbach C, Rohr KB, Selman M, Maher TM. Jenkins RG, et al. Among authors: cottin v. ERJ Open Res. 2024 Dec 16;10(6):00558-2023. doi: 10.1183/23120541.00558-2023. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39687396 Free PMC article.
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis.
Guédon AF, Carrat F, Mouthon L, Launay D, Chaigne B, Pugnet G, Lega JC, Hot A, Cottin V, Agard C, Allanore Y, Fauchais AL, Lescoat A, Dhote R, Papo T, Chatelus E, Bonnotte B, Kahn JE, Diot E, Aouba A, Magy-Bertrand N, Queyrel V, Le Quellec A, Kieffer P, Amoura Z, Granel B, Gaultier JB, Balquet MH, Wahl D, Lidove O, Espitia O, Cohen A, Fain O, Hachulla E, Mekinian A, Rivière S. Guédon AF, et al. Among authors: cottin v. RMD Open. 2024 Dec 9;10(4):e004918. doi: 10.1136/rmdopen-2024-004918. RMD Open. 2024. PMID: 39658051 Free PMC article.
Childhood interstitial lung disease survivors in adulthood: a European collaborative study.
Manali ED, Griese M, Nathan N, Uzunhan Y, Borie R, Michel K, Schwerk N, Fijolek J, Radzikowska E, Chua F, Pabary R, Mogulkoc N, McCarthy C, Kallieri M, Papaioannou AI, Kiper N, Koziar Vasakova M, Lacina L, Molina-Molina M, Torrent-Vernetta A, Tsiligiannis T, Karadag B, Kokosi M, Renzoni EA, Hm van Moorsel C, Campo I, Bendstrup E, Skovhus Prior T, Prasse A, Bonella F, Cottin V, Diesler R, Froidure A, Kolilekas L, Fotis L, Douros K, Kaditis AG, Jeny F, Chauveau S, Nunes H, Dahbia A, Mariani F, van der Vis JJ, Groen K, Erdem Eralp E, Gokdemir Y, Kocakaya D, Olgun Yildizeli S, Yalçın E, Emiralioğlu N, Nayir Buyuksahin H, O'Brien H, Karcıoglu O, Can D, Ezircan A, Kartal Ozturk G, Ocal N, Yuksel H, Narin Tongal S, Safrankova M, Kourtesi K, Louvrier C, Kannengiesser C, Fabre A, Legendre M, Crestani B, Pohunek P, Bush A, Papiris SA. Manali ED, et al. Among authors: cottin v. Eur Respir J. 2024 Dec 5:2400680. doi: 10.1183/13993003.00680-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39638417
Pulmonary fibrosis in patients with autoimmune pulmonary alveolar proteinosis: a retrospective nationwide cohort study.
Guirriec Y, Luque-Paz D, Bernard G, Mabo A, Kerjouan M, Ménard C, Monnier D, Nunes H, Uzunhan Y, Reynaud-Gaubert M, Bermudez J, Borie R, Crestani B, Traclet J, Wémeau-Stervinou L, Chenivesse C, Gomez E, Prévot G, Bourdin A, Bondue B, Bergeron A, Cottin V, Lederlin M, Jouneau S; OrphaLung network. Guirriec Y, et al. Among authors: cottin v. ERJ Open Res. 2024 Dec 2;10(6):00314-2024. doi: 10.1183/23120541.00314-2024. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39624377 Free PMC article.
Pulmonary Hypertension Associated With Trastuzumab-Emtansine: An Analysis of French PH Registry and WHO Pharmacovigilance Database.
Poisson C, Hlavaty A, Favrolt N, Chaumais MC, Grynblat J, Jutant EM, Lechartier B, Maurac A, Mouillot P, Palat S, Rambach L, Antigny F, Cottin V, Beltramo G, Humbert M, Khouri C, Bonniaud P, Montani D. Poisson C, et al. Among authors: cottin v. Chest. 2024 Nov 19:S0012-3692(24)05562-4. doi: 10.1016/j.chest.2024.11.006. Online ahead of print. Chest. 2024. PMID: 39571726 Free article.
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study.
Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, Jenkins RG, Scholand MB, Kreuter M, Valenzuela C, Ryerson CJ, Goldin J, Kim GHJ, Jurek M, Decaris M, Clark A, Turner SM, Barnes CN, Achneck HE, Cosgrove GP, Lefebvre ÉA, Flaherty KR. Lancaster L, et al. Among authors: cottin v. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241287307. doi: 10.1177/17534666241287307. Ther Adv Respir Dis. 2024. PMID: 39512136 Free PMC article. Review.
Pulmonary hypertension in patients carrying FLNA loss-of-function variants.
Stourm L, Grynblat J, Savale L, Lacoste-Palasset T, Jaïs X, Coulet F, Levy M, Meyrignac O, Ghigna MR, Cottin V, Sitbon O, Bonnet D, Goupil F, Humbert M, Gagnadoux F, Montani D; French PH Network PULMOTENSION Investigators. Stourm L, et al. Among authors: cottin v. Eur Respir J. 2024 Nov 7:2401132. doi: 10.1183/13993003.01132-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39510553
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Bauer-Ventura I, Bae SS, Lim D, Rivero-Gallegos D, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Perez Roman DI, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H, Aggarwal R, Cavagna L; Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators. Faghihi-Kashani S, et al. Arthritis Rheumatol. 2024 Oct 28. doi: 10.1002/art.43038. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39467037
Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Corte TJ, et al. Among authors: cottin v. Am J Respir Crit Care Med. 2024 Oct 11. doi: 10.1164/rccm.202405-0977OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39393084
723 results